About TORL BioTherapeutics
TORL BioTherapeutics is a company based in Los Angeles (United States) founded in 2019 by Mark Attanasio and Dave Licata. TORL BioTherapeutics has raised $412.3 million across 3 funding rounds from investors including ARE, TD Securities and Bristol-Myers Squibb. TORL BioTherapeutics offers products and services including TORL-1-23, TORL-2-307, TORL-3-600, and TORL-4-500. TORL BioTherapeutics operates in a competitive market with competitors including Moderna, BeiGene, Incyte, MorphoSys and Annexon, among others.
- Headquarter Los Angeles, United States
- Founders Mark Attanasio, Dave Licata
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Torl Biotherapeutics, Llc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$412.3 M (USD)
in 3 rounds
-
Latest Funding Round
$96 M (USD), Series C
Oct 07, 2025
-
Investors
ARE
& 9 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of TORL BioTherapeutics
TORL BioTherapeutics offers a comprehensive portfolio of products and services, including TORL-1-23, TORL-2-307, TORL-3-600, and TORL-4-500.
Targets CLDN6 for treating advanced cancers
Treats CLDN18.2+ solid tumors
Addresses CDH17+ colorectal cancer
Targets DLK1 positive solid tumors
People of TORL BioTherapeutics
Unlock access to complete
Funding Insights of TORL BioTherapeutics
TORL BioTherapeutics has successfully raised a total of $412.3M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $96 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in TORL BioTherapeutics
TORL BioTherapeutics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, TD Securities and Bristol-Myers Squibb.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Deep Track Capital is engaged in biotechnology investment activities.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Investments are focused on agtech, renewable energy, and transportation sectors.
|
Locked | Locked | Locked |
Investor details for TORL BioTherapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by TORL BioTherapeutics
Investment portfolio details for TORL BioTherapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - TORL BioTherapeutics
Detailed financials for TORL BioTherapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Torl Biotherapeutics Comparisons
Peer comparison for TORL BioTherapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of TORL BioTherapeutics
TORL BioTherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, MorphoSys and Annexon, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
ALX Oncology is focused on advancing cancer treatment therapies.
|
Detailed competitors of TORL BioTherapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Torl Biotherapeutics
Complete news archive for TORL BioTherapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TORL BioTherapeutics
TORL BioTherapeutics was founded in 2019 and raised its 1st funding round 4 years after it was founded.
TORL BioTherapeutics is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Dave Licata is the current CEO of TORL BioTherapeutics. They have also founded this company.
TORL BioTherapeutics is a funded company, having raised a total of $412.3M across 3 funding rounds to date.
TORL BioTherapeutics was founded in 2019 and is based in Los Angeles, United States. Antibody-based therapeutics are developed by the company for oncology indications. The lead candidate, TORL-1-23, is a CLDN6-directed antibody-drug conjugate targeted at multiple cancer types. A pipeline of preclinical antibody-drug conjugates and monoclonal antibodies is also advanced in various oncologic areas.
TORL BioTherapeutics's top competitors include Moderna, BeiGene and Strand Therapeutics.
TORL BioTherapeutics offers TORL-1-23, TORL-2-307, TORL-3-600, and TORL-4-500.
TORL BioTherapeutics has 10 investors. Key investors include ARE, TD Securities, Bristol-Myers Squibb, University of California, and Xontogeny.